4-[4,4-bis(4-fluorophenyl)butyl]-N-ethylpiperazine-1-carboxamide;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethylpiperazine-1-carboxamide;hydron;chloride
• 化学式: C23H30ClF2N3O
• 分子量: 438.0
• InChiKey: OEQHKNWFXHBJIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.65
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods for treating, diagnosing and prognosing a haematological malignancy
  申请人：Institut De Recerca Contra La Leucemia Josep Carreras

  公开号：EP2959904A1

  公开（公告）日：2015-12-30

  The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionallly, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and/or type 2 5-HTR.

  本发明涉及一种选自1型5-HTR抑制剂和2型5-HTR抑制剂的血清素受体（5-HTR）抑制剂，用于预防和/或治疗血液恶性肿瘤。此外，本发明还涉及基于检测 1 型 5-HTR 和/或 2 型 5-HTR 的表达来鉴定或分离血液恶性肿瘤中的恶性细胞或诊断血液恶性肿瘤的体外方法。此外，本发明还涉及根据 1 型 5-HTR 和/或 2 型 5-HTR 的水平确定预后、监测治疗效果或设计血液恶性肿瘤患者定制疗法的体外方法。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• METHOD OF TREATING THERAPY-RESISTANT SCHIZOPHRENIA WITH AMPEROZIDE
  申请人：Kabi Pharmacia AB

  公开号：EP0517787A1

  公开（公告）日：1992-12-16
• NEW USE OF DIPHENYLBUTYLPIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS
  申请人：KABI PHARMACIA AB

  公开号：EP0538422A1

  公开（公告）日：1993-04-28
• METHODS OF SCREENING USING AMPHIBIANS
  申请人：Brändli, André W.

  公开号：EP2409149B1

  公开（公告）日：2015-11-11